ORIC Pharmaceuticals to present Phase 1b enozertinib data in first-line lung cancer at ESMO 2026
ORIC•ORIC Pharmaceuticals will review ongoing Phase 1b enozertinib trial data in a webcast on October 23, 2026, ahead of a presentation at the ESMO Congress on October 26.
1. Enozertinib trial update
ORIC Pharmaceuticals will review ongoing Phase 1b enozertinib trial data during a webcast at 8 a.m. ET on October 23, 2026. The study targets previously untreated metastatic lung cancer with atypical EGFR mutations, and findings will be presented October 26 at the ESMO Congress.
2. Other planned presentations
Planned presentations also include a Phase 3 rinzimetostat combination study in previously treated metastatic prostate cancer. A separate rinzimetostat poster reports restricted cellular plasticity in preclinical models and mechanistic proof of concept in prostate cancer patient samples.
